Phentermine is FDA-approved strictly as a short-term weight-loss aid, but researchers have studied it for a surprisingly wide range of other conditions, from binge eating disorder and cocaine dependence to fatty liver disease. None of these uses have earned formal regulatory approval, and much of the evidence comes from small trials or animal studies. Still, the drug’s pharmacological profile, particularly how it affects brain chemicals beyond just suppressing appetite, has made it an ongoing subject of investigation in areas most people would never associate with a diet pill.
Why Phentermine’s Mechanism Opens the Door to Other Uses
Phentermine belongs to the amphetamine family of stimulants, and its most potent effect in the brain is releasing norepinephrine, the chemical messenger tied to alertness, arousal, and the “fight or flight” response. That norepinephrine release is what suppresses appetite, but it also has downstream effects on mood, attention, and reward-seeking behavior. In laboratory studies comparing several amphetamine-type stimulants, researchers found that the oral doses producing subjective stimulant effects in humans correlated with their potency for releasing norepinephrine rather than dopamine.1Synapse. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
Phentermine does also boost dopamine, the brain chemical most associated with pleasure and reward. Animal studies using microdialysis in rats showed that phentermine increased dopamine levels in the striatum in a dose-dependent manner, while having little measurable effect on serotonin.2International Journal of Obesity. Effects of phentermine on striatal dopamine and serotonin release in conscious rats: In vivo microdialysis study This combination of norepinephrine and dopamine activity, without major serotonin effects, gives phentermine a pharmacological fingerprint that researchers have tried to exploit for conditions where those particular brain chemicals are dysregulated.
Binge Eating Disorder and Bulimia
The most clinically developed off-label application for phentermine involves binge eating disorder and, to a lesser extent, bulimia nervosa. These conditions involve compulsive overeating episodes driven not by hunger but by psychological distress and impaired impulse control. The logic behind using phentermine here goes beyond its appetite-suppressing properties: the drug’s effects on dopamine and norepinephrine may help normalize the disrupted reward circuitry that fuels binge episodes.
The strongest evidence comes from the combination of phentermine with topiramate (an anticonvulsant), sold commercially as Qsymia for weight loss. In a randomized, placebo-controlled crossover trial of patients with binge eating disorder or bulimia nervosa, the number of binge-eating days over a four-week period dropped from about 16 at baseline to roughly 4 on the phentermine-topiramate combination, compared to about 13 on placebo. Nearly two-thirds of patients on the active drug achieved complete abstinence from binge eating, versus fewer than one in ten on placebo.3PubMed. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa
An open-label study examining the same combination found similar benefits: significant reductions in binge-eating frequency alongside improvements in measures of eating disorder severity and obsessive-compulsive symptoms that often co-occur with binge eating.4PubMed Central. Combination Phentermine–Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study It is worth noting that topiramate itself has independent anti-binge effects, so untangling how much of the benefit comes from phentermine alone versus the combination is difficult. Still, the results have been promising enough that some eating disorder specialists prescribe the combination off-label, particularly for patients whose binge eating coexists with obesity.
Cocaine and Stimulant Dependence
This one surprises most people: researchers have investigated phentermine as a potential treatment for cocaine addiction. The idea is rooted in what addiction medicine calls “agonist substitution therapy,” the same principle behind using methadone for opioid dependence. You replace a dangerous, highly addictive substance with a milder one that partially activates the same brain pathways, easing withdrawal and cravings without the devastating highs and lows.
Phentermine, as an amphetamine-type compound that boosts dopamine and norepinephrine at lower intensities than cocaine or methamphetamine, fits this profile. In rhesus monkeys trained to self-administer cocaine, phentermine treatment decreased cocaine-seeking behavior at doses that had little or no effect on food-seeking behavior, suggesting the reduction was not simply a matter of general sedation or malaise.5The Journal of Pharmacology and Experimental Therapeutics. Effects of Phentermine on Responding Maintained under Multiple Fixed-Ratio Schedules of Food and Cocaine Presentation in the Rhesus Monkey Both single-dose and repeated daily treatment reduced cocaine self-administration more than it reduced food intake, which is the key selectivity researchers look for in a potential addiction medication.
A broader review of appetite suppressants as potential treatments for stimulant dependence noted that amphetamine-type anorectics are logical candidates for normalizing brain chemistry disrupted by chronic stimulant abuse, though few clinical studies had tested them rigorously in human patients at the time of publication.6PubMed. Appetite suppressants as agonist substitution therapies for stimulant dependence The idea remains largely in the research phase. No addiction treatment guidelines currently recommend phentermine for stimulant dependence, and prescribing a Schedule IV controlled substance to someone with a stimulant use disorder raises obvious concerns. But the pharmacological rationale is sound, and some clinical case reports have described reductions in cocaine use among patients taking phentermine.
Alcohol Consumption and Withdrawal
Animal research has also explored phentermine’s effects on alcohol intake, though the evidence here is thinner and mostly limited to rat models. In one study, the combination of phentermine with fenfluramine (a serotonin-releasing agent that was later pulled from the market over heart valve concerns) produced a moderate reduction in alcohol consumption in rats. More striking was the finding that the combination completely prevented alcohol withdrawal seizures, a potentially life-threatening complication of heavy drinking cessation.7PubMed. Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats
Because fenfluramine was removed from the market after being linked to heart valve damage and pulmonary hypertension in humans, the specific phentermine-fenfluramine combination is no longer a viable clinical option. Phentermine on its own was not tested in isolation in that study, so it is unclear how much of the alcohol-related benefit was driven by phentermine versus fenfluramine versus their interaction. The research is interesting as a proof-of-concept that stimulant-class medications can modulate alcohol reward pathways, but it has not advanced meaningfully since fenfluramine’s withdrawal. Anyone hoping phentermine alone could help manage drinking would be getting ahead of the evidence.
Fatty Liver Disease
Nonalcoholic fatty liver disease is closely tied to obesity, so it stands to reason that a weight-loss drug might improve liver health as a secondary benefit. But a small pilot study specifically looked at whether phentermine could reduce hepatic steatosis (the medical term for fat buildup in the liver) in patients preparing for bariatric surgery. In the phentermine group, the proportion of patients with fatty liver on ultrasound dropped from about 91 percent to 72 percent, and the share with a completely normal liver ultrasound roughly tripled, from 9 percent to 28 percent. The placebo group showed no such improvement.8Medical Principles and Practice. Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study
The results just missed the threshold for statistical significance, which is not uncommon in very small pilot studies. They hint that phentermine may help clear liver fat, but whether that effect goes beyond what you would expect from weight loss alone is an open question. The researchers framed it as a potential pre-surgical benefit: reducing liver size and fat content before bariatric surgery can make the operation technically easier and safer. Larger, controlled studies would be needed before anyone could confidently recommend phentermine specifically for fatty liver, but the preliminary data is at least encouraging enough to study further.
Mood, Depression, and the Psychiatric Gray Area
Phentermine’s relationship with mood is complicated and somewhat paradoxical. Because it releases norepinephrine and dopamine, two chemicals targeted by many antidepressants, some patients report feeling better emotionally while taking it. A sense of increased energy, motivation, and well-being is common in the early weeks of use. This has led to speculation that phentermine could have antidepressant-like properties.
The reality is messier. A review of phentermine’s psychiatric effects found conflicting evidence: some case reports suggested phentermine could induce depression in certain patients, while others found no such link. The authors proposed three possible explanations: phentermine might trigger depression in a specific vulnerable subgroup, the effect might be dose-dependent, or the association might be coincidental.9PubMed Central. Phentermine, sibutramine and affective disorders The review also noted that phentermine’s potency in the central nervous system is comparatively low relative to other amphetamine-type stimulants, which might explain why its mood effects are unpredictable.
For people with preexisting mood disorders, this unpredictability matters. Some patients taking phentermine for weight loss report improvements in depression symptoms that they attribute to the drug, while others experience anxiety, irritability, or mood crashes, particularly as the drug wears off each day. No controlled clinical trial has tested phentermine specifically as an antidepressant, and the scattered case report evidence is too thin to draw any directional conclusions. If you are taking phentermine and notice significant mood changes, positive or negative, that information is worth sharing with your prescriber rather than assuming the drug is either helping or hurting your mental health.
Off-Label Use Is More Common Than You Might Think
Phentermine has been on the market since 1959, making it one of the longest-surviving prescription weight-loss drugs in the United States. Its age, low cost, and wide familiarity among prescribers have contributed to off-label prescribing practices that extend well beyond the conditions discussed above. Literature reviews have noted that phentermine is often prescribed long-term and for several off-label indications, which increases the potential for adverse drug interactions, especially in patients taking other medications.10PubMed Central. Potential drug-drug interactions with phentermine among long-term phentermine consumers: A retrospective analysis
The FDA approved phentermine only for short-term use (generally defined as a few weeks), but many clinicians prescribe it for months or even years, treating the “short-term” label as a regulatory artifact rather than a hard clinical limit. A large electronic health records study found that among patients who used phentermine for longer periods, the rate of serious cardiovascular events or death was low, with no significant difference between longer-term and shorter-term users.11PubMed. Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort That finding, while reassuring, comes from observational data rather than a randomized trial, so it cannot fully rule out risks that a controlled study might detect.
The gap between how phentermine is formally approved and how it is actually used creates a somewhat unusual regulatory situation. Doctors are legally permitted to prescribe any approved drug for off-label uses, and many do so with phentermine. But patients should understand that “off-label” means the evidence for that particular use has not been reviewed by the FDA, and the prescriber is relying on their own clinical judgment and whatever published research is available.
What Keeps These Uses From Becoming Official
Given the variety of conditions where phentermine shows at least preliminary promise, a reasonable question is why none of these uses have moved toward formal approval. Several factors work against it. Phentermine is generic, inexpensive, and produced by multiple manufacturers, none of whom have a financial incentive to fund the large, expensive clinical trials the FDA would require for a new indication. A randomized trial large enough to prove phentermine treats binge eating disorder or cocaine dependence could cost tens of millions of dollars, with no patent-protected payoff for the company that funds it.
Phentermine’s classification as a Schedule IV controlled substance also creates friction. Any expanded indication increases the total volume of prescriptions, which draws scrutiny from the Drug Enforcement Administration. Advocacy for broader phentermine use bumps up against decades-old anxieties about amphetamine-class drugs, which persist even though phentermine’s abuse potential is considered low relative to amphetamine itself. The historical association with the fen-phen disaster of the 1990s, when the combination of phentermine with fenfluramine caused fatal heart valve damage, also left a lasting stigma on phentermine by association, despite the fact that the cardiac problems were attributed to fenfluramine and dexfenfluramine, not phentermine.
There is also the question of whether phentermine even needs new indications to be prescribed for these conditions. Since off-label prescribing is both legal and common, a motivated clinician can already prescribe phentermine for binge eating or as part of an addiction management plan without waiting for FDA action. The lack of formal approval mostly affects insurance coverage and prescribing guidelines, not whether an individual doctor can write the prescription.
How Phentermine Compares to Newer Weight-Loss Drugs in Off-Label Potential
The arrival of GLP-1 receptor agonists like semaglutide and tirzepatide has reshaped the obesity treatment landscape, and these newer drugs are also being investigated for a strikingly similar set of off-label conditions: binge eating disorder, substance use disorders, fatty liver disease, and mood regulation. Their mechanism is different from phentermine’s, working through gut hormone pathways rather than amphetamine-like stimulant effects, but the overlap in potential off-label targets speaks to how closely obesity is interwoven with these other conditions.
For patients and clinicians, the practical comparison often comes down to cost and access. Phentermine is available as an inexpensive generic, typically costing a fraction of what a monthly supply of a GLP-1 agonist runs without insurance. That price difference matters for off-label use especially, because insurers are unlikely to cover any drug for an unapproved indication. A patient interested in trying medication for binge eating who cannot afford or access a newer drug may find phentermine to be the only realistic option, even if the evidence behind it is smaller in scale.
The trade-off is that phentermine’s stimulant properties bring side effects that GLP-1 drugs do not: elevated heart rate, increased blood pressure, insomnia, dry mouth, and the theoretical risk of psychological dependence. For someone with uncontrolled hypertension or a history of stimulant misuse, phentermine may be flatly unsuitable regardless of the off-label indication under consideration, while a GLP-1 drug might not carry those same risks. The decision is always individual, and the newer drugs’ existence does not erase phentermine’s relevance so much as give both patients and doctors more options to weigh.
Conditions Where Phentermine Is Unlikely to Help
The scope of phentermine’s off-label investigation sometimes gets inflated in online discussion forums. It is worth being clear about where the drug has not shown meaningful promise. There is no credible evidence that phentermine treats attention deficit hyperactivity disorder, even though its stimulant mechanism might seem plausible for that condition. Dedicated ADHD medications operate at different receptor profiles and dosing regimens, and phentermine has never been tested in clinical trials for attention or executive function.
Similarly, phentermine has not been studied as a treatment for chronic fatigue, fibromyalgia, or cognitive decline, despite occasional anecdotal reports from patients who say they feel sharper or more energetic on the drug. Those subjective effects are consistent with the stimulant properties of any amphetamine-class medication and would be expected to fade with tolerance. Using phentermine for energy or focus in the absence of an obesity-related indication means taking on cardiovascular and psychological risks without evidence of sustained benefit.
Patients sometimes request phentermine hoping it will function as a mild, less stigmatized alternative to prescription amphetamines. Prescribers who understand the drug’s pharmacology recognize that while phentermine and amphetamine share a chemical family tree, they are not interchangeable. Phentermine’s lower potency for dopamine release makes it a poor substitute for conditions where robust dopaminergic stimulation is the therapeutic target. Its strengths, such as they are beyond weight loss, lie specifically in conditions where moderate norepinephrine and dopamine nudges, combined with appetite effects, happen to align with the underlying pathology.